Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine

Vaccine

Volumn 33, Issue 51, 2015, Pages 7245-7253

  Carignan, Damien ^a   Thérien, Ariane ^a   Rioux, Gervais ^a   Paquet, Geneviève ^a   Gagné, Marie Ève Laliberté ^a   Bolduc, Marilène ^a   Savard, Pierre ^a   Leclerc, Denis ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Influenza; M2e; Matrix protein 2; Nanoparticles; PapMV; Vaccine

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A ANTIBODY; INFLUENZA VACCINE; M2E PEPTIDE; NANOPARTICLE; PAPAYA MOSAIC VIRUS VACCINE; PROTEIN M2; UNCLASSIFIED DRUG; VIRUS VACCINE; CAPSID PROTEIN; DRUG CARRIER; HYBRID PROTEIN; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONSENSUS SEQUENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS; LETHAL DOSE; MORBIDITY; MOUSE; NONHUMAN; PAPAYA MOSAIC VIRUS; PHARMACEUTICAL ENGINEERING; PLANT VIRUS; PRIORITY JOURNAL; SINGLE DRUG DOSE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; GENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY; POTEXVIRUS; SURVIVAL ANALYSIS;

ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG CARRIERS; IMMUNOGLOBULIN G; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; POTEXVIRUS; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE; VIRAL MATRIX PROTEINS;

EID: 84955292261     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.10.123     Document Type: Article

References (37)

1. de Jong J., Rimmelzwaan G., Fouchier R., Osterhaus A. Influenza virus: a master of metamorphosis. J Infect 2000, 40:218-228.
2. Kelso J.K., Halder N., Milne G.J. Vaccination strategies for future influenza pandemics: a severity-based cost effectiveness analysis. BMC Infect Dis 2013, 13:81.
3. Liao Y.-C., Lin H.-H., Lin C.-H. Monitoring the antigenic evolution of human influenza A viruses to understand how and when viruses escape from existing immunity. BMC Res Notes 2013, 6:227.
4. Cox N.J., Trock S.C., Burke S.A. Pandemic preparedness and the Influenza Risk Assessment Tool (IRAT). Curr Top Microbiol Immunol 2014, 385:119-136.
5. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:36-44.
6. Pica N., Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 2013, 64:189-202.
7. Neirynck S., Deroo T., Saelens X. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5:1157-1163.
8. Ebrahimi S.M., Tebianian M., Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes 2011, 42:1-8.
9. Liu W., Zou P., Ding J., Lu Y., Chen Y.-H. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect 2005, 7:171-177.
10. Hughey P., Roberts P., Holsinger L. Effects of antibody to the influenza A virus M2 protein on M2 surface expression and virus assembly. Virology 1995, 212:411-421.
11. Mozdzanowska K., Maiese K., Furchner M., Gerhard W. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 1999, 254:138-146.
12. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172:5598-5605.
13. Wang R., Song A., Levin J., Dennis D., Zhang N.J., Yoshida H., et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 2008, 80:168-177.
14. El Bakkouri K., Descamps F., de Filette M., Smet A., Festjens E., Birkett A., et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011, 186:1022-1031.
15. Fiers W., De Filette M., El Bakkouri K., Schepens B., Roose K., Schotsaert M., et al. M2e-based universal influenza A vaccine. Vaccine 2009, 27:6280-6283.
16. Denis J., Majeau N., Acosta-Ramirez E., Savard C., Bedard M.-C., Simard S., et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology 2007, 363:59-68.
17. Lacasse P., Denis J., Lapointe R., Leclerc D., Lamarre A. Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation. J Virol 2008, 82:785-794.
18. Savard C., Guérin A., Drouin K., Bolduc M., Laliberté-Gagné M.-E., Dumas M.-C., et al. Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. PLoS ONE 2011, 6:e21522.
19. Denis J., Acosta-Ramirez E., Zhao Y., Hamelin M.-E., Koukavica I., Baz M., et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008, 26:3395-3403.
20. Babin C., Majeau N., Leclerc D. Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP. J Nanobiotechnol 2013, 11:10.
21. Rioux G., Babin C., Majeau N., Leclerc D. Engineering of papaya mosaic virus (PapMV) nanoparticles through fusion of the HA11 peptide to several putative surface-exposed sites. PLoS ONE 2012, 7:e31925.
22. Mathieu C., Rioux G., Dumas M.-C., Leclerc D. Induction of innate immunity in lungs with virus-like nanoparticles leads to protection against influenza and Streptococcus pneumoniae challenge. Nanomedicine 2013, 1-10.
23. Rioux G., Mathieu C., Russell A., Bolduc M., Laliberté-Gagné M.-E., Savard P., et al. PapMV nanoparticles improve mucosal immune responses to the trivalent inactivated flu vaccine. J Nanobiotechnol 2014, 12:19.
24. Gavett S.H., Chen X., Finkelman F., Wills-Karp M. Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia. Am J Respir Cell Mol Biol 1994, 10:587-593.
25. Israelski D.M., Araujo F.G., Conley F.K., Suzuki Y., Sharma S., Remington J.S. Treatment with anti-L3T4 (CD4) monoclonal antibody reduces the inflammatory response in toxoplasmic encephalitis. J Immunol 1989, 142:954-958.
26. Muth S., Schütze K., Hain T., Yagita H., Schild H., Probst H.C. A CD40/CD40L feedback loop drives the breakdown of CD8(+) T-cell tolerance following depletion of suppressive CD4(+) T cells. Eur J Immunol 2014, 44:1099-1107.
27. Sorge R.E., Martin L.J., Isbester K.A., Sotocinal S.G., Rosen S., Tuttle A.H., et al. Olfactory exposure to males, including men, causes stress and related analgesia in rodents. Nat Methods 2014, 11:629-632.
28. Liu W., Zou P., Chen Y.-H. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett 2004, 93:131-136.
29. Zou P., Liu W., Chen Y.-H. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection. Int Immunopharmacol 2005, 5:631-635.
30. Lebel M.-È., Daudelin J.-F., Chartrand K., Tarrab E., Kalinke U., Savard P., et al. Nanoparticle adjuvant sensing by TLR7 enhances CD8+ T cell-mediated protection from Listeria monocytogenes infection. J Immunol 2014, 192:1071-1078.
31. Schmitz N., Beerli R.R., Bauer M., Jegerlehner A., Dietmeier K., Maudrich M., et al. Universal vaccine against influenza virus linking TLR signaling to anti-viral protection. Eur J Immunol 2012, 42:863-869.
32. Huber V.C., Lynch J.M., Bucher D.J., Le J., Metzger D.W. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 2001, 166:7381-7388.
33. Squires R.B., Noronha J., Hunt V., García-Sastre A., Macken C., Baumgarth N., et al. Influenza research database: an integrated bioinformatics resource for influenza research and surveillance. Influenza Other Respir Viruses 2012, 6:404-416.
34. El-Manzalawy Y., Dobbs D., Honavar V. Predicting flexible length linear B-cell epitopes. Comput Syst Bioinform Conf 2008, 7:121-132.
35. Schotsaert M., Ysenbaert T., Neyt K., Ibañez L.I., Bogaert P., Schepens B., et al. Natural and long-lasting cellular immune responses against influenza in the M2e-immune host. Mucosal Immunol 2013, 6:276-287.
36. Kim M.-C., Lee Y.-N., Ko E.-J., Lee J.S., Kwon Y.-M., Hwang H.S., et al. Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection. Mol Ther 2014, 22:1364-1374.
37. Song J.-M., Van Rooijen N., Bozja J., Compans R.W., Kang S.-M. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A 2011, 108:757-761.